about
Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory StudyHigh-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsInhibition of tyrosine kinase receptor Tie2 reverts HCV-induced hepatic stellate cell activationInterferon-related genetic markers of necroinflammatory activity in chronic hepatitis CATA homozigosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study.Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link.Diversity of killer cell immunoglobulin-like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcomeIntrahepatic angiopoietin-2 correlates with chronic hepatitis C progression and is induced in hepatitis C virus replicon systems.Angiopoietin-2/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C.Correction for Quer at al., High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods.Evaluating a newly developed pharmacogenetic array: screening in a Spanish population.Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy.Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers.Preliminary evidence of sustained expression of angiopoietin-2 during monocyte differentiation in chronic hepatitis C.Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards.Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers.Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers.Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects.A predictive model of treatment outcome in patients with chronic HCV infection using IL28B and PD-1 genotyping.Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C.Allele and genotype frequencies of serotonin and dopamine transporter and receptor polymorphisms in a Norwegian population.Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis.Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis.Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis.Polymorphisms in CYP2D6 have a greater effect on variability of risperidone pharmacokinetics than genderEffect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteersEvaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockersDRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers
P50
Q28551216-670899DA-A014-4090-B123-792123BAA91FQ28652352-2C0693F4-92B1-44E9-A0F1-93E9381BFBFDQ30303127-0F3C50A0-53BF-4D15-BA12-1860BADF18A3Q33898567-474ACF41-B149-4624-B8C3-6B63B3C7178AQ33928098-EEF4E18C-5979-40C7-927C-7553B7F16601Q34792158-215D128E-F339-436F-B70E-2F0932FC122CQ35187793-B374EA18-F3B1-48A1-8586-ECA83825C0FBQ40405941-35505338-3720-46E9-8CF8-9D676FA7926BQ40428093-463CC4AB-CE75-4688-9681-20DC77351BD7Q40682456-7F985CA9-EA08-4DEE-803F-4FEA2EF7BE24Q42788951-B12184F8-6E0E-4EEC-A715-FC33DE07DC23Q42918749-41E95E33-AB00-4552-A526-0C434A3F4A63Q42991482-F8BABE03-10E7-41D5-934A-86099D523FF5Q43623861-2BF21253-A6ED-4D21-9192-B1729F8A177CQ44035049-FCF06A6B-F4AC-42BE-B36C-F3CC7089E421Q46254583-40B5DD26-BE43-4DE0-812B-111C7B845AB5Q46257861-E01CD589-2A57-40E7-916F-E8FBC843A5EFQ46434971-215E32F8-6190-428E-B837-E1C62A8CE43BQ47998134-7FD4C618-6257-4A0F-A3AB-13D53CC38DB8Q50026018-ED20808C-9A61-48EF-8F3C-9AF405E65D5BQ50465819-E252AE5A-8C2B-49E7-A2FD-F640826D8D3EQ50553399-959107BA-D544-44FE-A357-6BDD506CD7F5Q50554860-E3077C79-E1FD-427A-8600-1BB03019B9B4Q51806631-18F4A0A2-61EC-47AA-AB4B-108744C3D134Q52665701-0D4EBAD0-628C-46BB-B679-0BCF22835363Q53819679-52AF7B88-D4DB-4684-809E-9A1743A35D0DQ53820042-12E03C3C-C932-4C34-87CD-F37E047B3536Q57211998-6E96BBEF-F6A5-4584-A3F1-7083336FFFDEQ57212204-6D7ECFBF-B5C2-486A-9819-837ADEC7A346Q57212937-507B4C61-6FAA-4BF8-A830-04CFFC9DDC43Q57213864-FA47E008-8E10-4A6D-A70E-AD6B106D206B
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Rosario López-Rodríguez
@ast
Rosario López-Rodríguez
@en
Rosario López-Rodríguez
@es
Rosario López-Rodríguez
@nl
Rosario López-Rodríguez
@sl
type
label
Rosario López-Rodríguez
@ast
Rosario López-Rodríguez
@en
Rosario López-Rodríguez
@es
Rosario López-Rodríguez
@nl
Rosario López-Rodríguez
@sl
prefLabel
Rosario López-Rodríguez
@ast
Rosario López-Rodríguez
@en
Rosario López-Rodríguez
@es
Rosario López-Rodríguez
@nl
Rosario López-Rodríguez
@sl
P106
P21
P31
P496
0000-0002-4713-0633